Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

This study provides Class III evidence that alemtuzumab is more effective than interferon β-1a in reducing relapses and disability in patients with RRMS in a long-term follow-up of a rater-blinded, randomized clinical trial with 59.5% of patients participating in the extended follow-up period.